Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Global X Defense Tech ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Global X Defense Tech ETF trades at $61.38. Which is the better fit depends on your goals.
| ALNY | SHLD | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $78.02 |
52-Week Low | $278.09 | $58.20 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SHLD, the Global X Defense Tech ETF, trades at $61.19, down 0.44% on the day, with technical indicators showing a bearish trend. The ETF provides diversified exposure to global defense technology companies, benefiting from rising military spending worldwide. Recent news highlights focus on defense sector growth, with articles discussing the UK's $20 billion military overhaul and ongoing geopolitical tensions driving demand.
The outlook for SHLD is supported by structural increases in global defense budgets, but faces risks from political shifts and valuation concerns. Analyst sentiment is mixed, with some seeing a rebound opportunity from current levels, while technical weakness suggests near-term caution. The ETF's performance will hinge on sustained government spending and sector earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
